nach oben

Erschienen in:

01.06.2008 | Original Investigation

Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques

verfasst von: Yujuan Yue, Zhongde Wang, Kristina Abel, Jinliang Li, Lisa Strelow, Angelo Mandarino, Meghan K. Eberhardt, Kimberli A. Schmidt, Don J. Diamond, Peter A. Barry

Erschienen in: Medical Microbiology and Immunology | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

A vaccine consisting of rhesus cytomegalovirus (RhCMV) pp65-2, gB and IE1 expressed via modified vaccinia Ankara (MVA) was evaluated in rhesus macaques with or without prior priming with expression plasmids for the same antigens. Following two MVA treatments, comparable levels of anti-gB, pp65-2 and neutralizing antibody responses, and pp65-2- and IE1-specific cellular immune responses were detected in both vaccinated groups. Similar reductions in plasma peak viral loads were observed in these groups compared to untreated controls. This study demonstrates the immunogenicity and protective efficacy of rMVA-based RhCMV subunit vaccines in a primate host and warrants further investigation to improve the efficacy of subunit vaccines against CMV.

Adler SP, Plotkin SA, Gonczol E, Cadoz M, Meric C, Wang JB, Dellamonica P, Best AM, Zahradnik J, Pincus S, Berencsi K, Cox WI, Gyulai Z (1999) A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 180:843–846CrossRefPubMed

Baroncelli S, Barry PA, Capitanio JP, Lerche NW, Otsyula M, Mendoza SP (1997) Cytomegalovirus and simian immunodeficiency virus coinfection: longitudinal study of antibody responses and disease progression. JAIDS 15:5–15PubMed

Barry PA, Chang WLW (2007) Primate betaherpesviruses. In: Arvin A, Campadielli G, Moore P, Mocarski E, Roizman B, Whitley R, Yamanishi K (eds) Human herpesviruses: biology, therapy and Immunoprophylaxis. Cambridge University Press, London

Barry PA, Lockridge KM, Salamat S, Tinling SP, Yue Y, Zhou SS, Gospe SM Jr, Britt WJ, Tarantal AF (2006) Nonhuman primate models of intrauterine cytomegalovirus infection. ILAR J 47:49–64CrossRefPubMed

Buxbaum S, Kraus FB, Hahn A, Beck O, Kabartas B, Doerr HW, Ludwig B (2006) Flow cytometric analysis of virus-specific T lymphocytes: practicability of detection of HCMV-specific T lymphocytes in whole blood in patients after stem cell transplantation. J Immunol Methods 311:164–173CrossRefPubMed

Chang WL, Tarantal AF, Zhou SS, Borowsky AD, Barry PA (2002) A recombinant rhesus cytomegalovirus expressing enhanced green fluorescent protein retains the wild-type phenotype and pathogenicity in fetal macaques. J Virol 76:9493–9504CrossRefPubMedPubMedCentral

Drexler I, Staib C, Sutter G (2004) Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 15:506–512CrossRefPubMedPubMedCentral

Fowler KB, Stagno S, Pass RF (2003) Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289:1008–1011CrossRefPubMed

Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA (1992) The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663–667CrossRefPubMed

10.

Gonczol E, Berensci K, Pincus S, Endresz V, Meric C, Paoletti E, Plotkin SA (1995) Preclinical evaluation of an ALVAC (canarypox)—human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 13:1080–1085CrossRefPubMed

11.

Hansen SG, Strelow LI, Franchi DC, Anders DG, Wong SW (2003) Complete sequence and genomic analysis of rhesus cytomegalovirus. J Virol 77:6620–6636CrossRefPubMedPubMedCentral

12.

Huff JL, Eberle R, Capitanio J, Zhou SS, Barry PA (2003) Differential detection of B virus and rhesus cytomegalovirus in rhesus macaques. J Gen Virol 84:83–92CrossRefPubMed

13.

Loomis-Huff JE, Eberle R, Lockridge KM, Rhodes G, Barry PA (2001) Immunogenicity of a DNA vaccine against herpes B virus in mice and rhesus macaques. Vaccine 19:4865–4873CrossRefPubMed

14.

Nigro G, Adler SP, La Torre R, Best AM (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350–1362CrossRefPubMed

15.

Pass RF, Duliege AM, Boppana S, Sekulovich R, Percell S, Britt W, Burke RL (1999) A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 180:970–975CrossRefPubMed

16.

Robinson HL, Montefiori DC, Villinger F, Robinson JE, Sharma S, Wyatt LS, Earl PL, McClure HM, Moss B, Amara RR (2006) Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology 352:285–294CrossRefPubMed

17.

Schleiss MR, Bourne N, Bernstein DI (2003) Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis 188:1868–1874CrossRefPubMed

18.

Schleiss MR, Bourne N, Stroup G, Bravo FJ, Jensen NJ, Bernstein DI (2004) Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 189:1374–1381CrossRefPubMed

19.

Stratton KR, Durch JS, Lawrence RS (2000) Vaccines for the 21st century: a tool for decisionmaking. National Academy Press, Washington, DC

20.

Wang Z, La Rosa C, Lacey SF, Maas R, Mekhoubad S, Britt WJ, Diamond DJ (2006) Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J Clin Virol 35:324–331CrossRefPubMed

21.

Wang Z, La Rosa C, Li Z, Ly H, Krishnan A, Martinez J, Britt WJ, Diamond DJ (2007) Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine 25:1132–1141CrossRefPubMed

22.

Wang Z, La Rosa C, Maas R, Ly H, Brewer J, Mekhoubad S, Daftarian P, Longmate J, Britt WJ, Diamond DJ (2004) Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 78:3965–3976CrossRefPubMedPubMedCentral

23.

Wyatt LS, Belyakov IM, Earl PL, Berzofsky JA, Moss B (2008) Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology (in press)

24.

Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG (1981) Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 98:281–287CrossRefPubMed

25.

Yue Y, Kaur A, Eberhardt MK, Kassis N, Zhou SS, Tarantal AF, Barry PA (2007) Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques. J Virol 81:1095–1109CrossRefPubMed

26.

Yue Y, Kaur A, Zhou SS, Barry PA (2006) Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65). J Gen Virol 87:777–787CrossRefPubMed

27.

Yue Y, Zhou SS, Barry PA (2003) Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques. J Gen Virol 84:3371–3379CrossRefPubMed

28.

Zhong J, Khanna R (2007) Vaccine strategies against human cytomegalovirus infection. Expert Rev Anti Infect Ther 5:449–459CrossRefPubMed

Titel: Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques
verfasst von: Yujuan Yue
Zhongde Wang
Kristina Abel
Jinliang Li
Lisa Strelow
Angelo Mandarino
Meghan K. Eberhardt
Kimberli A. Schmidt
Don J. Diamond
Peter A. Barry
Publikationsdatum: 01.06.2008
Verlag: Springer Berlin Heidelberg
Erschienen in: Medical Microbiology and Immunology / Ausgabe 2/2008
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-008-0074-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

MHC class I immune evasion in MCMV infection

The history of cytomegalovirus and its diseases

Human cytomegalovirus infection and antiviral immunity in septic patients without canonical immunosuppression

Role of the cytomegalovirus major immediate early enhancer in acute infection and reactivation from latency

CD8 T-cell-based immunotherapy of cytomegalovirus infection: “proof of concept” provided by the murine model

Interplay between human cytomegalovirus and dendritic cells in T cell activation